3-(tert-butylthio)pyrrolidine-2,5-dione | 90998-27-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 3-(tert-butylthio)pyrrolidine-2,5-dione
• 英文别名: 3-(tert-Butylsulfanyl)pyrrolidine-2,5-dione；3-tert-butylsulfanylpyrrolidine-2,5-dione
• CAS: 90998-27-9
• 化学式: C₈H₁₃NO₂S
• 分子量: 187.263
• InChiKey: JMGCCZKAYGFSBU-UHFFFAOYSA-N

物化性质

• 熔点：
  124 °C(Solv: cyclohexane (110-82-7))
• 沸点：
  350.3±35.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  71.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  马来酰亚胺 、 2-甲基-2-丙硫醇钠盐 在 叔丁基硫醇 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以100%的产率得到3-(tert-butylthio)pyrrolidine-2,5-dione
  参考文献：
  名称：

  Jimenez, M. Angeles; Ortega, M. Carmen; Tito, Amelia, Heterocycles, 1984, vol. 22, # 5, p. 1179 - 1187

  摘要：

  DOI：

文献信息

• Jimenez, M. Dolores; Ortega, Raquel; Tito, Amelia, Heterocycles, 1988, vol. 27, # 1, p. 173 - 184
  作者：Jimenez, M. Dolores、Ortega, Raquel、Tito, Amelia、Farina, Francisco

  DOI：——

  日期：——
• JIMENEZ, M. A.;ORTEGA, M. C.;TITO, A.;FARINA, F., HETEROCYCLES, 1984, 22, N 5, 1179-1187
  作者：JIMENEZ, M. A.、ORTEGA, M. C.、TITO, A.、FARINA, F.

  DOI：——

  日期：——
• Relaxin Prodrugs
  申请人：ASCENDIS PHARMA RELAXIN DIVISION A/S

  公开号：US20160296600A1

  公开（公告）日：2016-10-13

  The present invention relates to a carrier-linked relaxin prodrug, pharmaceutical compositions comprising said prodrug, their use as medicaments for the treatment of diseases which can be treated with relaxin, methods of application of such carrier-linked relaxin prodrug or pharmaceutical compositions, methods of treatment, and containers comprising such prodrug or compositions.
• Novel Polymeric hGH Prodrugs
  申请人：Ascendis Pharma Endocrinology Division A/S

  公开号：US20170354716A1

  公开（公告）日：2017-12-14

  The present invention relates to a polymeric human growth hormone prodrug and dry, liquid and reconstituted pharmaceutical formulations comprising said prodrug. It furthermore relates to their use as medicaments for the treatment of diseases which can be treated with growth hormone and to methods of treatment. It also relates to methods of application of such polymeric human growth hormone prodrug or pharmaceutical formulation.
• OPTICAL IMAGING AGENTS TARGETING INFLAMMATION
  申请人：SORBONNE UNIVERSITE

  公开号：US20200368373A1

  公开（公告）日：2020-11-26

  The present invention relates to an optical imaging agent of formula (SIGNAL) n -SUPPORT-(L-BIOVECTOR) m , wherein: SUPPORT represents a physiologically acceptable chemical or biological substrate, with a particle size of between 1 and 100 nm, SIGNAL is a fluorophore, L is a linker of formula —C(X)—R 1 —Y—, with X being O, NH or S R 1 being a (C 1 -C 6 )alkyl group, optionally R 1 being a (C 1 -C 6 )alkyl group, optionally interrupted by 1 to 3 groups selected from —O—, —NH—, —C(O)—, —NHC(O)—, —(O)CNH—, —C(O)NH—N═C—, —N═C—, and (I), Y being NH or a —(O)CNH— group, and BIOVECTOR is a carbohydrate targeting markers of inflammation, advantageously selected from the group consisting of mannose, sialyl Lewis X and derivatives thereof, n is greater than or equal to 0.5 and is less than 2, m is between 0 and 30, preferably between 1 and 30, more preferably between 5 and 20, diagnostic compositions comprising same and use thereof as a diagnostic agent (in vivo or ex vivo), or as contrast agent for image-guided surgery.